Loading...
Loading...
Available on 1 platform
Sign in to view source links and access this dataset
237 calls from 225 individuals reported 692 adverse events to a centralized call center for the Minnesota Medical Cannabis Program between 2015 and 2021. The data, authored by Sílvia M. Illamola, includes symptom severity, product formulation, and daily THC/CBD doses, with 32.5% of cases leading to treatment discontinuation. This retrospective analysis provides real-world safety signals for cannabinoid therapies.
Data is provided in a DOCX file format, which may require conversion for analysis. License is CC-BY-4.0.